Background Detection of asymptomatic ischemia in patients with coronary artery disease has been associated with increased risk for adverse outcome, but treatment of patients with asymptomatic ischemia remains controversial. Accordingly, the purpose of this study was to determine if treatment reduces adverse outcome in patients with daily life ischemia.
Methods and Results A multicenter, randomized, doubleblind, placebo-controlled study of asymptomatic or minimally symptomatic outpatients with daily life silent ischemia due to coronary artery disease was conducted. The primary outcome measure was event-free survival at 1 year by Kaplan-Meier analysis. Events were death, resuscitated ventricular tachycardia/fibrillation, myocardial infarction, hospitalization for unstable angina, aggravation of angina, or revascularization. The secondary outcome was ischemia during ambulatory ECG monitoring at 4 weeks. Three hundred six outpatients with mild or no angina (Canadian Cardiovascular Society class I or II), abnormal exercise tests, and ischemia on ambulatory monitoring were randomized to receive either atenolol (100 mg/d) or placebo. After It is generally accepted that the presence of myocardial ischemia is associated with an increased risk of untoward events in patients with coronary artery disease (CAD). Recently, numerous studies have focused on the most common form of ischemia, asymptomatic or silent ischemia, identified during routine daily life by ambulatory electrocardiogram (AECG) monitoring.'-3 In many studies, patients with AECGdetected ischemia have had an increased risk for adverse outcome compared with patients without AECG-monitored ischemia.4-22 Anti-ischemic treatment is frequently used in such patients, but no prospective controlled studies of anti-ischemic treatment have been published to address whether treatment of patients with ischemia during daily life is associated with reduced risk of adverse outcome.
To test the hypothesis that anti-ischemic treatment would reduce the risk of adverse outcome among patients with asymptomatic ischemia during daily life, we conducted a prospective, randomized, double-blind study comparing the effects of an anti-ischemic agent (atenolol) with placebo. We enrolled only asymptomatic and minimally symptomatic patients (class I or II, Canadian Cardiovascular Society) in an attempt to focus on treatment given specifically for daily life ischemia rather than treatment required for symptom control.
Methods
This multicenter study was investigator initiated and designed (see "Appendix" for sites and principal investigators). Site initiation, special training in AECG monitoring, and patient recruitment commenced January 2, 1990 , and the first patient qualified for entry on January 18, 1990. Briefly, after Pepine et al Treatment of Daily Life Ischemia 763 screening (2 weeks), eligible patients entered a 2-week, singleblind, placebo period during which baseline history, physical examination, exercise testing (Bruce protocol), and AECG monitoring were done. Those meeting eligibility criteria were randomized, entered a double-blind, placebo-controlled treatment period and were followed until an end point was reached. The study was overseen by an executive steering committee chaired by an executive director responsible for the overall conduct of the study. The study was monitored by an independent data and safety monitoring committee (DSMC). The protocol was approved by the institutional review board at each participating site. Informed consent was obtained from each patient.
Eligibility
Potentially eligible patients were identified from those who had previously presented with CAD, and no attempt was made to screen the general asymptomatic population. To be eligible, patients of either sex and any age were required to have (1) documented CAD evidenced by either coronary angiography (>50% diameter stenosis of a major coronary artery) or a previously documented myocardial infarction and (2) anticipated need for either }3-blocker or calcium antagonist treatment; and heart failure, greater than first-degree atrioventricular block, asthma, or other contraindications to p-blockade therapy.
A real-time AECG system network was designed to deal with practical problems associated with large-scale, long-term AECG monitoring for multicenter trials. Each site was trained by the same workers, used the same equipment and instruction sheets, and was linked electronically with the AECG core laboratory facility. A detailed description of the system designed for this study appears elsewhere.24 Briefly, this system allows for analog-to-digital conversion and ECG signal processing within the monitor (Monitor One Omni, Q-Med) in real time. AECG data were downloaded for rapid transmission by modem from the site, immediate confirmation of signal quality and lead position, objective analysis, physician overreading, and transmission of results to the site using a validated system for ST-segment and heart rate analysis. In addition, each qualifying patient's baseline AECG lead pattern was stored and compared with follow-up AECG lead patterns to ensure that the leads were recording from the same position in each patient. Sites were blinded to all AECG data. No AECG results were available to the physicians or patients during the study. An ischemic episode was defined as a period of horizontal or downsloping ST-segment depression of 21 mm, persisting for .1 minute, and separated from another episode by >1 minute.2,25 To qualify for randomization, patients meeting entry criteria were required to demonstrate either two or more asymptomatic ischemic episodes or a single asymptomatic episode with a duration of .5 minutes during 48 hours of AECG monitoring in the placebo lead-in period.
Randomization and Treatment
At the end of the placebo lead-in period, patients meeting the above entry criteria were randomly assigned to receive either placebo or atenolol according to a computer-generated random code. Study investigators and patients were told to assume that they were taking atenolol and to conduct themselves accordingly. Study drugs (atenolol or matching placebo) were supplied (as Tenormin by ICI/Zeneca Pharmaceuticals) in 50-and 100-mg tablets. All patients were started at 100 mg daily, titratable to 50 mg should limiting side effects develop.
Follow-up
The patients were followed at 4, 15, 26, 39, and 52 weeks or whenever interim evaluations were required for symptoms, events, or side effects. At the 4-, 26-, and 52-week visits, AECG monitoring was done.
Assessment of Treatment Effect
The primary study outcome measure was event-free survival at 1 year. The following ischemia-related events were considered end points: death, resuscitation from ventricular tachycardia/fibrillation (VT/VY), nonfatal myocardial infarction, hospitalization for unstable angina, aggravation of angina requiring known antianginal therapy, and need for revascularization. All patients reaching end points and their supporting data (eg, ECGs and hospital records) were reviewed by the DSMC, and the classification of events was made by the DSMC.
The event that occurred first was considered the primary end point, so that if a patient developed unstable angina and was hospitalized and then while hospitalized developed a myocardial infarction and died, unstable angina was the primary end point for that patient. Myocardial infarction was considered an end point when a patient was hospitalized and infarction was documented by ECG and/or enzyme criteria without recognizable antecedent unstable angina. Unstable angina was used as an end point when the patient required hospitalization because the severity or the pattern of anginal pain had changed (eg, crescendo or rest) without documentation of myocardial infarction. All patients included in this category had clinical and ECG changes of ischemia without ECG or enzyme changes of infarction and were hospitalized before exiting the protocol. Aggravation of angina was used as an end point when the patient's clinical picture had changed so that a 50% chance of placebo therapy was no longer acceptable. The patient required either medical therapy (eg, openlabel antianginals) or revascularization treatment (eg, percutaneous transluminal coronary angioplasty [PTCA] or coronary artery bypass grafting, [CABG] ). The patient in this category may require hospitalization for the actual intervention (catheterization, PTCA, or CABG) but not for the pattern of chest pain. Thus, for patients who developed new-onset or increased angina, were given known antianginal therapy, or were admitted for catheterization and then had CABG, this aggravation classification was used. Need for revascularization was used as an end point in the rare case that this intervention occurred in the absence of altered symptoms such as reinterpretation of a previous angiogram or the decision to undertake revascularization because of patient or physician choice despite lack of change in the clinical picture. The secondary measure of treatment effect was AECG monitoring of ischemia at 4 weeks.
Blinding to Treatment
Blinding to treatment was maintained by the executive coordinator, executive committee, the DSMC, study investigators and coordinators, and patients throughout both interim analyses. At the termination of the study, investigators and study nurses were told to assume that patients had been treated with atenolol and to consider replacement of study medication with a known ,l-blocker in a dose comparable to that received during the study. This was done as an attempt to prevent possible 8-blockade withdrawal phenomena.
Statistical Analysis
All analyses were performed on an intention-to-treat basis. ferences comparing baseline characteristics of the two treatment groups.
Exercise ECG data at baseline revealed that the heart rate achieved at onset of 1.0-mm ST-segment depression was 127±17 (mean±SD) and 126±17 beats per minute in the placebo and atenolol groups, respectively. There were no significant differences in heart rate, systolic or diastolic blood pressures, or exercise time at onset ischemia comparing the two groups.
The average heart rate was 75.1±12.9 beats per minute, and there were 4.4±4.6 ischemic episodes per 48 hours in the placebo group patients during AECG monitoring ( Table 2 ). The average heart rate was 75.3+11.9 beats per minute, and there were 3.6+4.2 ischemic episodes per 48 hours in the atenolol group patients. The average duration of AECG ischemia was 36.6+±4.1 minutes per 48 hours in the placebo group patients and 30.0+3.3 minutes per 48 hours in the atenolol group patients. None of these AECG values at baseline were significantly different comparing placebo and atenolol groups. acceleration to effect a change of one class), 30 17 patients in the accelerated angina group (11 placebo and 6 atenolol) would be considered to have unstable angina. Thus, using the less restricted definition, 17 placebo-assigned and 10 atenolol-assigned patients developed unstable angina, and the probability of serious events noted above using the common definition of unstable angina was RR, 0.56; 95% CI, 0.29 to 1.03; P=.06.
The possible role of other anti-ischemic therapy was also considered. Overall, there were 38 events in the 210 patients taking aspirin (18%) and 18 (19%) in the 96 patients not taking aspirin. Among the placebo-and atenolol-assigned patients, there were no significant differences in frequency of events whether or not they took aspirin. Overall, there were 19 events in the 105 patients taking long-acting nitrates (18%) and 37 (18%) events in the 201 not taking nitrates. Among the placebo-and atenolol-assigned patients, there were no significant differences in frequency of events whether or not they took long-acting nitrates. Among variables summarized in Tables 1 and 2 
